ライフサイエンスコーパス: nicotine dependence

1 type, inhalation depth, Fagerstrom-assessed nicotine dependence).

2 s and, instead, may contribute to continuing nicotine dependence.

3 ntrol animals, suggesting a role for NRG3 in nicotine dependence.

4 CI, 52%-89%) and 98% (95% CI, 95%-100%) for nicotine dependence.

5 tress disorder; other anxiety disorders; and nicotine dependence.

6 ing, including use of medicines to help with nicotine dependence.

7 rbB4 signaling may be an important factor in nicotine dependence.

8 nificantly reduced cigarette consumption and nicotine dependence.

9 mokers and for smokers with a high degree of nicotine dependence.

10 ts for the treatment of comorbid alcohol and nicotine dependence.

11 is gene variant modulates various aspects of nicotine dependence.

12 ognitive/affective alterations that underlie nicotine dependence.

13 the pharmacotherapy of Parkinson disease and nicotine dependence.

14 s associated with an elevated risk for later nicotine dependence.

15 e exposure directly increases level of later nicotine dependence.

16 , placebo-controlled trials of naltrexone in nicotine dependence.

17 receptor (nAChR) influence both ethanol and nicotine dependence.

18 s a critical relay circuit in the control of nicotine dependence.

19 onset of regular smoking predicted level of nicotine dependence.

20 appear to be involved in the later stages of nicotine dependence.

21 ning processes contribute to the etiology of nicotine dependence.

22 and is thought to be a critical component of nicotine dependence.

23 tinic receptor variants that affect risk for nicotine dependence.

24 RNA6-CHRNB3 gene clusters that contribute to nicotine dependence.

25 associated with comorbid cocaine, opium, and nicotine dependence.

26 istical Manual (fourth edition) diagnosis of nicotine dependence.

27 associated with a protective effect against nicotine dependence.

28 al molecular component in the development of nicotine dependence.

29 disorders including Parkinson's disease and nicotine dependence.

30 nd loci reported for other smoking traits to nicotine dependence.

31 and controls to test for an association with nicotine dependence.

32 tine dependence with the Fagerstrom Test for Nicotine Dependence.

33 ghlighted in previous studies of smoking and nicotine dependence.

34 be new pharmacotherapeutics for treatment of nicotine dependence.

35 obiology, genetic etiology, and treatment of nicotine dependence.

36 CHRNA3-CHRNB4) and both smoking quantity and nicotine dependence.

37 TA DA neuronal function, DA transmission and nicotine dependence.

38 rug reinforcement and has been implicated in nicotine dependence.

39 nes (i.e., TAS2R16 and TAS2R38) in affecting nicotine dependence.

40 lele association with smoking initiation and nicotine dependence.

41 ntrolled for, with the possible exception of nicotine dependence.

42 o and number of cigarettes smoked per day or nicotine dependence.

43 nabis dependence; the second, on alcohol and nicotine dependence.

44 have been implicated in various measures of nicotine dependence.

45 tanding of the genetic mechanisms underlying nicotine dependence.

46 as measured by using the Fagerstrom Test for Nicotine Dependence.

47 ors (nAChRs) play a role in both alcohol and nicotine dependence.

48 s that can be long lasting and contribute to nicotine dependence.

49 ted in behavioural responses to nicotine and nicotine dependence.

50 ors contribute in part to the development of nicotine dependence.

51 nce to nervous system function, disease, and nicotine dependence.

52 files associated with alcohol, cannabis, and nicotine dependence.

53 m function, some of which must contribute to nicotine dependence.

54 g toward elucidating the basic mechanisms of nicotine dependence.

55 ntake, may be a key trigger of withdrawal in nicotine dependence.

56 nicotine in a key brain circuit involved in nicotine dependence.

57 an hormones on the etiology and treatment of nicotine dependence.

58 riant, but not the N variant associated with nicotine dependence.

59 dly linked to addictive disorders, including nicotine dependence.

60 CHRNA4 and tested them for association with nicotine dependence.

61 HRNB4 gene cluster and smoking heaviness and nicotine dependence.

62 ain dopamine D2-type autoreceptors influence nicotine dependence.

63 le is known about the role of this system in nicotine dependence.

64 ence syndrome they were 1.72 (1.57-1.87) for nicotine dependence, 2.67 (2.38-2.99) for cannabis depen

65 rsion disorder (5.3%; 95% CI, 4.3% to 6.2%), nicotine dependence (4.5%; 95% CI, 3.6% to 5.4%), alcoho

66 , performance in both tasks was modulated by nicotine dependence, abstinence, and pharmacological man

67 s the most significantly associated SNP with nicotine dependence across five independent cohorts (tot

68 significant increases were seen in 12-month nicotine dependence (adjusted risk difference=2.6%) and

69 Results indicate that a history of nicotine dependence affects subsequent nicotine- but not

70 mia nervosa), and four were "externalizing" (nicotine dependence, alcohol dependence, drug abuse or d

71 anxiety disorder; suicidal ideation/attempt; nicotine dependence; alcohol abuse/dependence; and illic

72 ne self-administration and initial stages of nicotine dependence, alpha7 homomeric nAChRs appear to b

73 the CHRNA5-CHRNA3-CHRNB4 region that predict nicotine dependence also predicted a later age at smokin

74 ancy is associated with an increased risk of nicotine dependence among adult offspring.

75 sion subside, as indicated by high levels of nicotine dependence among individuals with remitted depr

76 ng pregnancy is a risk factor for subsequent nicotine dependence among offspring.

77 pendence (adjusted risk difference=2.6%) and nicotine dependence among users (adjusted risk differenc

78 ncreases in 12-month nicotine dependence and nicotine dependence among users suggests that increases

79 use, DSM-IV nicotine dependence, and DSM-IV nicotine dependence among users were analyzed to test th

80 es in nicotine use, nicotine dependence, and nicotine dependence among users were statistically signi

81 However, interacting effects of chronic nicotine dependence and acute nicotine withdrawal on cog

82 ng reward, E-cigs might maintain a degree of nicotine dependence and also serve as a noncombustible s

83 ard, e-cigarettes might maintain a degree of nicotine dependence and also serve as non-combustible su

84 t increase the risks of both lung cancer and nicotine dependence and associated smoking behavior.

85 is available on the co-occurrence of DSM-IV nicotine dependence and Axis I and II psychiatric disord

86 Nicotine dependence and cocaine abuse are major public h

87 tify a novel regulatory SNP association with nicotine dependence and connect, for the first time, pre

88 l data showed the genetic pleiotropy between nicotine dependence and COPD or lung function.

89 data show an increased risk for the onset of nicotine dependence and drug abuse or dependence in pers

90 nes that were reported to be associated with nicotine dependence and found significant joint action b

91 3239-rs12720071-rs806368 was associated with nicotine dependence and FTND score in the 2 samples (P <

92 -1 gene dysfunctions have been implicated in nicotine dependence and in autism spectrum disorders.

93 erest because of its apparent involvement in nicotine dependence and in the control of dopamine relea

94 thought to influence both susceptibility to nicotine dependence and its comorbid behavioral traits i

95 ence was measured by the Fagerstrom test for nicotine dependence and level of craving.

96 linked to smoking-related behaviors such as nicotine dependence and level of smoking.

97 ith recent reports of NRXN3 association with nicotine dependence and linkage with opiate dependence,

98 low mRNA expression of CHRNA5, the risk for nicotine dependence and lung cancer is significantly low

99 ine receptors (AChRs) that increases risk of nicotine dependence and lung cancer.

100 at are associated with an increased risk for nicotine dependence and lung cancer.

101 two distinct mechanisms conferring risk for nicotine dependence and lung cancer: altered receptor fu

102 type has recently been genetically linked to nicotine dependence and lung cancer; however, the mode o

103 al clinical applications in the treatment of nicotine dependence and many neuropsychiatric conditions

104 n of the CRF-CRF(1) system may contribute to nicotine dependence and may represent a prominent target

105 t may be beneficial in the treatment of both nicotine dependence and MDD.

106 rface expression levels are modulated during nicotine dependence and multiple disorders of the nervou

107 use relative to larger increases in 12-month nicotine dependence and nicotine dependence among users

108 disorders, and individuals who have comorbid nicotine dependence and other psychiatric disorders.

109 et for the discovery of novel medication for nicotine dependence and other substance-related disorder

110 insula plays a critical role in maintaining nicotine dependence and reactivity to smoking cues.

111 use, and rs6495309 has been associated with nicotine dependence and risk for lung cancer.

112 bipolar disorder, major depressive disorder, nicotine dependence and schizophrenia).

113 -level understanding of the insula's role in nicotine dependence and shows a relationship between inh

114 Striatal BPND was correlated negatively with nicotine dependence and smoking exposure.

115 Combining genetic and mechanistic studies of nicotine dependence and smoking heaviness may reveal nov

116 A5-CHRNA3-CHRNB4) previously associated with nicotine dependence and smoking quantity traits.

117 Associations between nicotine dependence and specific Axis I and II disorders

118 To independently assess the effects of nicotine dependence and stimulation of the nicotinic ace

119 and in relationships between midbrain BPND, nicotine dependence and striatal dopamine D2-type recept

120 GluR5 is a pathogenetic mechanism underlying nicotine dependence and the high relapse rate in individ

121 In this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry

122 Nicotine dependence and veteran-reported physician-diagn

123 SNPs in EGLN2 are also associated with nicotine dependence and with smoking efficiency (CO/CPD)

124 ion, echoing the increased susceptibility to nicotine dependence and withdrawal noted for adolescent

125 le provides an overview of recent studies of nicotine dependence and withdrawal that used genetically

126 ove our understanding of the neurobiology of nicotine dependence and withdrawal.

127 ing, nicotine dependence (Fagerstrom Test of Nicotine Dependence), and cessation difficulties were ev

128 Weighted estimates of nicotine use, DSM-IV nicotine dependence, and an approximation of the Fagerst

129 ed initiation of all types of substance use, nicotine dependence, and cannabis abuse/dependence (for

130 ture phenotypes of persistent heavy smoking, nicotine dependence, and cessation failure.

131 contributes to initiation, regular smoking, nicotine dependence, and cessation.

132 12-month prevalences of nicotine use, DSM-IV nicotine dependence, and DSM-IV nicotine dependence amon

133 Implications for conceptualizing risk for nicotine dependence, and its treatment, are discussed.

134 associated with increased smoking rate, high nicotine dependence, and low self-efficacy.

135 h few exceptions, increases in nicotine use, nicotine dependence, and nicotine dependence among users

136 Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or

137 that could be important in the treatment of nicotine dependence, and perhaps other neurological dise

138 ypes in the CNR1 gene may alter the risk for nicotine dependence, and the associations are likely sex

139 We apply this method to a GWAS of nicotine dependence, and use simulated data to test it o

140 Major depressive disorder (MDD) and nicotine dependence are highly comorbid, with studies sh

141 ecting risk for vulnerability to cocaine and nicotine dependence as well as bipolar disorder, suggest

142 CYP2A6 genotype is not associated with nicotine dependence, as defined by the Fagerstrom Test o

143 sk for lung cancer is direct or an effect of nicotine dependence, as evidence for both scenarios exis

144 datasets: the Collaborative Genetic Study of Nicotine Dependence (ascertained for tobacco use disorde

145 2 in lung), and expression of genes spanning nicotine dependence-associated variants is enriched in c

146 This can be used to prioritize nicotine dependence association studies through a straig

147 % with cannabis use disorder, and 56.6% with nicotine dependence at baseline.

148 4-77%) was associated with increased risk of nicotine dependence at P=3.7 x 10(-8) (odds ratio (OR)=1

149 dence among users suggests that increases in nicotine dependence between the 2001-2002 and 2012-2013

150 quire replication, offer novel insights into nicotine dependence biology.

151 pregnancy are at elevated risk of developing nicotine dependence but not marijuana dependence as adul

152 ) have recently been shown to play a role in nicotine dependence, but it is not clear which nAChR sub

153 conduct an empirical study of progression of nicotine dependence by applying the WNA approach to thre

154 s analyzed in several brain areas related to nicotine dependence by immunofluorescence techniques.

155 rols, 45% female) treated in the Mayo Clinic Nicotine Dependence Center between 1988 and 2000.

156 vances in the understanding and treatment of nicotine dependence, close to 21% of adults in the Unite

157 nterest, and participant-reported ratings of nicotine dependence, craving, and self-efficacy were col

158 rt a genome-wide association study (GWAS) of nicotine dependence defined on the basis of scores on th

159 ndence, as defined by the Fagerstrom Test of Nicotine Dependence, demonstrating that cigarettes smoke

160 he primary eligibility criteria were current nicotine dependence (DSM criteria), smoking 10 or more c

161 daily smoking, progression to heavy smoking, nicotine dependence (Fagerstrom Test of Nicotine Depende

162 1862416 is not associated, likely reflecting nicotine dependence features not captured by the heavine

163 g smokers both with and without a history of nicotine dependence; for other outcomes, increases were

164 garettes smoked per day, Fagerstrom Test for Nicotine Dependence (FTND) and Motivation to Quit (MTQ)

165 ine concentration (COT), Fagerstrom test for nicotine dependence (FTND) and schizophrenia to examine

166 or addiction by both the Fagerstrom Test for Nicotine Dependence (FTND) and the Revised Tolerance Que

167 ddiction assessed by the Fagerstrom test for nicotine dependence (FTND) has received little attention

168 metabolizers) had lower Fagerstrom Test for Nicotine Dependence (FTND) scores, suggesting lower leve

169 The Fagerstrom test for nicotine dependence (FTND) was used to assess dependence

170 We present a Fagerstrom Test for Nicotine Dependence (FTND)-based genome-wide association

171 sed with scores from the Fagerstrom Test for Nicotine Dependence (FTND).

172 measure for ND using the Fagerstrom Test for Nicotine Dependence (FTND).

173 analysis of items on the Fagerstrom Test for Nicotine Dependence gave evidence of three classes perti

174 recently the pre-eminence of this system in nicotine dependence has been challenged.

175 ing that cigarettes smoked per day (CPD) and nicotine dependence have distinct genetic correlates.

176 animal models that replicate key features of nicotine dependence have led to important advancements i

177 the involvement of alpha6 nAChR subunits in nicotine dependence have only recently emerged.

178 fluenced regulation in brain on the risks of nicotine dependence, heavy smoking and consequent lung c

179 derable evidence supports a genetic risk for nicotine dependence; however, less is known about the ph

180 four SNPs in the CHRNB2 gene with respect to nicotine dependence in a collection of 901 subjects (815

181 nd multiple measures of smoking behavior and nicotine dependence in a large, national representative

182 in CHRNB4 are associated with lower risk for nicotine dependence in African Americans and European Am

183 in the development and maintenance of strong nicotine dependence in cigarette smokers posit (i) a rap

184 A5) is the strongest genetic risk factor for nicotine dependence in European Americans and contribute

185 e basis of scores on the Fagerstrom Test for Nicotine Dependence in European-American (EA) and Africa

186 ale smokers but not in male smokers and with nicotine dependence in female but not in male smokers.

187 l signs, and has a protective effect against nicotine dependence in human genetic association studies

188 ggest potential utility for the treatment of nicotine dependence in humans.

189 ther investigation of R-MOD for treatment of nicotine dependence in humans.

190 AChR) family genes that are known to mediate nicotine dependence in mammals, suggesting functional co

191 pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.

192 h was negatively associated with severity of nicotine dependence in slow metabolizers.

193 ses to other primary reinforcers that govern nicotine dependence in smokers.

194 iants were associated with increased risk of nicotine dependence in the European American primary sam

195 ever, the role of rare variation in risk for nicotine dependence in these nicotinic receptor genes ha

196 or a significantly (P =.004) lower risk (for nicotine dependence, in the prospective data) in persons

197 ransition from smoking to the development of nicotine dependence, including an amino acid change in t

198 s, (1) whether the genetic predisposition of nicotine dependence influence COPD risk and lung functio

199 e identified who would benefit from targeted nicotine dependence intervention programs to help them i

200 ronically exposed to nicotine, implying that nicotine dependence involves the sensitization of nicoti

201 Nicotine dependence is a serious public health concern.

202 Nicotine dependence is influenced by chromosome 15q25.1

203 Nicotine dependence is one of the world's leading causes

204 ion is predispositional to or resultant from nicotine dependence is unclear.

205 the mechanisms underlying its involvement in nicotine dependence is unclear.

206 ine responses; however the role of CaMKIV in nicotine dependence is unknown.

207 elicit both the acute and chronic effects of nicotine dependence is unknown.

208 cles of smoking and withdrawal contribute to nicotine dependence, long-term alterations in brain rewa

209 Ethnicity, weight, and level of nicotine dependence may help identify smokers who have g

210 nhanced understanding of these dimensions of nicotine dependence may help to advance progress toward

211 ge was 47.2 years (IQR 36.3-54.5), with high nicotine dependence (mean 24 cigarettes per day [SD 13.2

212 A modestly elevated risk for nicotine dependence might be an exception.

213 rsisted longer in smoking heavily, developed nicotine dependence more frequently, were more reliant o

214 6969968-A alleles together increased risk of nicotine dependence more than each variant alone: P = 3.

215 iew, we address these issues by developing a nicotine dependence (ND) genetic susceptibility map base

216 didate gene studies for smoking behavior and nicotine dependence (ND) have disclosed too few predispo

217 ne (GABAB2) were tested for association with nicotine dependence (ND) in an extensively phenotyped co

218 Nicotine dependence (ND) is a moderately heritable trait

219 ase (DDC) locus with the DSM-IV diagnosis of nicotine dependence (ND) or a quantitative measure for N

220 etic and environmental factors in regulating nicotine dependence (ND) risk, including the effects on

221 is an independent risk factor for offspring nicotine dependence (ND), but mechanisms remain unknown.

222 acetylcholine receptors (nAChR) subunits and nicotine dependence (ND), only few studies were performe

223 holine receptor subunits are associated with nicotine dependence (ND).

224 ificantly associated with the progression of nicotine dependence (ND).

225 ccount for at least 50% of the liability for nicotine dependence (ND).

226 likely to harbor susceptibility gene(s) for nicotine dependence (ND).

227 een posttraumatic stress disorder (PTSD) and nicotine dependence (ND).

228 ement in the development of vulnerability to nicotine dependence (ND).

229 study reported that NRXN1 is associated with nicotine dependence (ND); this, together with the intrig

230 nomenon that is thought to contribute to the nicotine dependence of cigarette smokers.

231 ch in the neurobiologic and genetic basis of nicotine dependence offers promise for the development o

232 dissociation between the effects of chronic nicotine dependence on neural representations of reward

233 Furthermore, the effect of prior history of nicotine dependence on subsequent nicotine and alcohol t

234 ving a 2-fold increase in risk of developing nicotine dependence once exposed to cigarette smoking.

235 e to traumatic events increases the risk for nicotine dependence or alcohol or other drug use disorde

236 None of the trials assessed nicotine dependence or interest in quitting at any point

237 mprehensive, such as the Fagerstrom Test for Nicotine Dependence or the American Psychiatric Associat

238 to have a diagnosis of drug use disorder or nicotine dependence or to have used tobacco than their n

239 use disorder: OR, 2.6; 95% CI, 1.6-4.4; and nicotine dependence: OR, 1.7; 95% CI, 1.2-2.4), but not

240 applicable), cigarette consumption, level of nicotine dependence, other confounders, definition of qu

241 identifying cellular/receptor mechanisms of nicotine dependence, our results take a step toward impr

242 riers as assessed by the Fagerstrom Test for Nicotine Dependence (P=1.2 x 10(-4)).

243 t a biological level and are associated with nicotine dependence phenotypes.

244 nterdisciplinary approach to the genetics of nicotine dependence provides a model for testing how fun

245 u-opioid receptor (OPRM1) genotype, or their nicotine dependence questionnaire score (phenotype).

246 Participants with lower levels of nicotine dependence responded better than those with hig

247 Two behaviors central to nicotine dependence, reward and anxiety relief, were exa

248 Nicotine dependence risk and lung cancer risk are associ

249 ed differences in CHRNA5 mRNA expression and nicotine dependence risk to underlying DNA methylation d

250 her other CHRNA5 coding variation influences nicotine dependence risk, we performed targeted sequenci

251 g variants are independently associated with nicotine dependence risk.

252 , lower CHRNA5 mRNA expression and increased nicotine dependence risk.

253 ation studies, we provide evidence that both nicotine-dependence risk and lung cancer risk are influe

254 d number of cigarettes smoked per day, and a nicotine dependence scale.

255 d positively with higher Fagerstrom Test for Nicotine Dependence score (r = .58, p = .031) and more c

256 GWAS analysis considered Fagerstrom Test for Nicotine Dependence score as an ordinal trait, separatel

257 dary, quantitative phenotype, the Fagerstrom nicotine dependence score, that is correlated with COPD

258 with ND measured by the Fagerstrom Test for Nicotine Dependence score; of these, 11 SNPs remained si

259 icotine-dependent cases (Fagerstrom Test for Nicotine Dependence score4) and 1238 non-dependent contr

260 Finally, relationships with nicotine dependence scores showed enhanced response in i

261 elopment of brain-based biomarkers to assess nicotine dependence severity and treatment efficacy are

262 etween cingulate-striatal brain circuits and nicotine dependence severity as indexed by the intensity

263 um that negatively correlated with increased nicotine dependence severity but was unaffected by acute

264 ecies ACC-striatal circuit relationship with nicotine dependence severity is dysregulated following c

265 In addition, individuals with greater nicotine dependence severity show increased engagement o

266 y and functional connectivity are related to nicotine dependence severity.

267 connectivity in 116 smokers with a range of nicotine dependence severity.

268 e relationship between ACC-striatal rsFC and nicotine dependence severity.

269 withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or

270 in Hb-IP circuits, a key pathway involved in nicotine dependence.SIGNIFICANCE STATEMENT This study un

271 Severity of nicotine dependence significantly correlated with dopami

272 utcomes of smoking, as well as predictors of nicotine dependence, smoking initiation, and smoking ces

273 Nicotine dependence (SNP-based heritability = 8.6%) is g

274 Our results highlight nicotine dependence-specific loci, emphasizing the FTND

275 of Cell, Feng et al. report a worm model of nicotine dependence that shows behavioral adaptations su

276 f the most powerful and extensive studies of nicotine dependence to date and has found novel risk loc

277 de association study (GWAS) meta-analysis of nicotine dependence, totaling 38,602 smokers (28,677 Eur

278 Here we examine the effects of nicotine dependence (trait; smokers (n = 24) vs. non-smo

279 ng rate, number of recent quit attempts, and nicotine dependence; two key mediators of smoking cessat

280 We found the genetic predisposition of nicotine dependence was associated with COPD risk, even

281 Nicotine dependence was examined using logistic regressi

282 y smoking, number of cigarettes per day, and nicotine dependence was greater in females than in males

283 Nicotine dependence was measured by the Fagerstrom test

284 Nicotine dependence was measured by using the Fagerstrom

285 variation contributes to the development of nicotine dependence, we performed a comprehensive genome

286 nAChRs and/or cell types that play a role in nicotine dependence, we studied these receptors and cell

287 ver genetic variants that influence risk for nicotine dependence, we targeted over 300 candidate gene

288 The odds of progressing from smoking to nicotine dependence were almost twice as great for offsp

289 Rates of drug use disorders and nicotine dependence were also elevated compared with the

290 an approximation of the Fagerstrom Test for Nicotine Dependence were compared for the 2001-2002 NESA

291 or 10 years on average, and met criteria for nicotine dependence were given SPECT scans on two days:

292 problem gambling and alcohol, cannabis, and nicotine dependence were obtained at age 21 years.

293 spring smoking behavior and lifetime risk of nicotine dependence were obtained by structured intervie

294 Nicotine dependence, which reduces the likelihood of qui

295 as Neurexin 1 (NRXN1), in the development of nicotine dependence while also identifying a known candi

296 Optimal treatment of nicotine dependence will require greater understanding o

297 Using a rat model of nicotine dependence with longitudinal fMRI measurements,

298 and Negative Syndrome Scale (PANSS) and for nicotine dependence with the Fagerstrom Test for Nicotin

299 cingulate cortex (dACC) plays a key role in nicotine dependence, with its functional connections bet

300 variant, Ser9Gly (rs6280) has been linked to nicotine dependence, yet the mechanisms underlying its i